CoChat

The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review

Ruan, Zhen, Yang, Lisong, Shi, Honghao, Yue, Xiaomeng, Wang, Yao, Liang, Miaoying, Hu, Hao · 2021 · Expert Review of Pharmacoeconomics & Outcomes Research

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

Abstract

Introduction: As a novel glucagon-like peptide-1receptor agonist (GLP-1 RA) for type 2 diabetes (T2D) treatment, the economic value of once-weekly semaglutide had been assessed in several country settings. The authors’ objective was to systematically review the existing pharmacoeconomic literature evaluating the cost-effectiveness associated with once-weekly semaglutide compared with other GLP-1 RAs and provide implications for further researches.Areas covered: We conducted a systematic literature review of cost-effectiveness analysis (CEA) published up to 25 July 2020 in PubMed, web of science, and the ISPOR presentation database, compared once-weekly semaglutide with other GLP-1 RAs in T2D. Nineteen studies were identified, including 8 short-term and 11 long-term studies. General characteristics and main results of the included studies were summarized.Expert opinion: This review provided references for other countries to overview the value of once-weekly semaglutide compared with other GLP-1 RAs in T2D in the healthcare decision-making process and to conduct their CEA studies associated with once-weekly semaglutide. The authors found that the cardiovascular (CV) benefit of once-weekly semaglutide was under-estimated in current studies and suggested that the methods of economic evaluations for novel anti-diabetic drugs with CV benefit should be improved in future researches.

Overview

Integrity signals

Registry

Crossref · 10.1080/14737167.2021.1860022

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 62 references

Research works printed but not linked: 4

  1. Capehorn MS, 2019, Diabetes Metab
  2. Pollock RF, 2019, Diabetic Med, 36, 170
  3. Tikkanen CK, 2018, Management, 12, 12
  4. de Wit HM, 2017, Neth J Med, 75, 272

Cited by

See all 16

Metadata

Authors
Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H.
Affiliations
  • University of Macau (MO)
  • University of Cincinnati (US)
  • Imperial College London (GB)
Corresponding author
Hu, Hao
Venue
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2021-01-12
Volume
21
Issue
2
Pages
221-233
ISSN
  • 1473-7167 (ISSN-L)
  • 1744-8379
OpenAlex
W3111172371
Cited by
15
References
62
Citations by year
2025: 2 · 2024: 4 · 2023: 4 · 2022: 5
FWCI
0.34
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Pharmacoeconomics & Outcomes Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
semaglutide, GLP-1 receptor agonists, type 2 diabetes, cost-effectiveness, cardiovascular benefits, economic evaluation, antidiabetic drugs, healthcare decision-making
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Economics, Pharmaceutical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. https://app.cochat.ai/papers/10.1080/14737167.2021.1860022
The paper
Ruan, Z., Yang, L., Shi, H., Yue, X., Wang, Y., Liang, M., & Hu, H. (2021). The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2021.1860022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.